2009 Fiscal Year Final Research Report
3"O-methylEGCG (metylated-(3")-epigallocatechin gallate) regulated the cellular proliferation in hepatoma cell line Huh7 in vitro and in vivo.
| Project/Area Number |
19590797
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Gastroenterology
|
|---|
| Research Institution | Kurume University |
|---|
Principal Investigator |
HASHIMOTO Osamu Kurume University, 医学部, 助教 (50289427)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
UENO Takato 久留米大学, 先端癌治療研究センター, 教授 (70176618)
|
|---|
| Project Period (FY) |
2007 – 2009
|
| Keywords | メチル化カテキン / 肝癌治療 |
|---|
| Research Abstract |
We herein report a new finding, namely, the anti-proliferate potential of MethylEGCG and attempt to clarify its mechanism of action against a Huh7 hepatoma cell line. inhibition by flow cytometry. MethylEGCG was found to induce cell proliferation at a very low concentration (5uM). The expression of pAkt was down-regulated after treatment at concentrations under 5uM. We observed the in vivo growth of a tumor graft model (5×10^6 Huh7 cells grafted in the skin of nude mice). The tumor growth of the 1mg/1kg MethylEGCG i.p and 7.5mg/kg MethylEGCG orally group showed a significant difference (after 2 weeks, vs. control ; p<0.05 and after 3 weeks, vs control ; p<0.01(n=12)). In summary, these findings suggest that MethylEGCG may be an important chemoprevention agent for the treatment of hepatoma.
|
